Personalized Medicine – No Longer Star Trek, It’s Real
Partnership involves developing a product to analyze and interpret human genomic variations
Informatics start-up GenoSpace recently joined our Life Sciences Partner Ecosystem to work with us in developing a product to analyze and interpret human genomic variations. The companies will work together to develop an integrated product offering for the analysis and interpretation of human genomic variation.
The GenoSpace platform seeks to establish secure, cloud-based online communities and customized research portals that connect physicians, individuals, and researchers who are interested in using clinical and genomic information; as well as to provide analysis and interpretation tools that support personalized medicine. An essential part of this process will be the detection and annotation of gene variants. We are in the unique position to collect, annotate and publish a gene variant database and will work with GenoSpace to make this data available to its customers.
Through our Thomson Reuters Life Sciences Partner Ecosystem, the GenoSpace platform will provide access to an unprecedented amount of curated, medically relevant data – from pathway and disease biology to regulatory and financial information. The combination of GenoSpace's expertise in integrating clinical and complex -omics data, coupled with the proven history of manual curation of complex data by Thomson Reuters, the partnership will help enable the realization of personalized medicine. Thomson Reuters and GenoSpace will produce a curated database of genomic variation, with an emphasis on medical and scientific utility.
"The barrier to establishing personalized medicine is no longer generating data, but analyzing and interpreting it," said John Quackenbush, GenoSpace's CEO. "By coupling our technology to synthesize genomic and clinical data with the unparalleled information resources that Thomson Reuters has created, we are positioned to lead the implementation of personalized medicine."
"We are delighted to welcome GenoSpace to our Partner Ecosystem," said Joseph Donahue, senior vice president at Thomson Reuters. "Together, we will be able to provide hospitals, health systems, disease foundations and pharmaceutical research organizations with large scale clinical genomic data sets and tools to help in annotating and interpreting genomic variation and support better informed medical treatment decisions."
"Next-generation sequencing – NGS – is vital in understanding how to achieve personalized medicine," explained Andreas Matern, Thomson Reuters Vice President of Disruptive Innovation. "The pharma market is investing in it, and it will come to fruition reasonably soon. Thinking about long term, personalized medicine is no longer Star Trek, it’s real."
GenoSpace, LLC is a Cambridge, Massachusetts-based company that is pioneering a bold and innovative software platform for advancing 21st-century genomic medicine. Founded in 2011 on the principle that individuals should own and control access to their own genomic data, GenoSpace has built a robust software system for securely storing vast amounts of genomic data and makes it available to individuals and groups who need to connect with each other and share data.